Infertility Clinical Trial
Official title:
Dosage Optimization for Letrozole Treatment in Clomiphene Resistant Patients With Polycystic Ovary Syndrome: A Prospective Interventional Study
In a prospective interventional study, 44 Clomiphene resistant infertile patients were selected from Abolfazl Infertility Clinic of Bushehr University of Medical Sciences. Letrozole was given orally in a dose of 2.5mg, 5mg and 7.5mg, respectively. If the patient displayed no response, the dosage was increased. The size of follicle, endometrial thickness, estradiol, complications and clinical pregnancy rate were evaluated as the final outcome.
In this prospective intervention, the investigators studied Abolfazle outpatients who were
referred to us by Bushehr University of Medical Sciences in Iran between January 1, 2008 and
December 30, 2010. The study was approved by the institutional Ethics Committee of Bushehr
University of Medical Sciences and all patients were required to provide written informed
consent before the study commenced.There were 3 steps in which the investigators prescribed
letrozole (Femara,Novartis,Quebec,Canada). In all cases, daily administration began on the
3rd day of the menstrual cycle through to the 7th day (totaling 5 days). In the first step
the investigators prescribed letrozole at a dose of 2.5 mg (one tablet) for one or two
cycles according to the patient's response. Normal follicular size and endometrial thickness
were considered 18-24 mm and 6 mm or more respectively.1 If the follicle was deemed not
acceptable, the dose of letrozole was increased at the next cycle.
At the second and third steps the investigators prescribed letrozole at a dose of 5 mg daily
and 7.5 mg/day,respectively and according to patient's response, repeat the same dose.
In the current study the investigators tested the hypothesis that prescribing letrozole as
an ovulation induction agent in infertile women would increase pregnancy rate, ovulation and
follicle number (at the normal size range of 18-24 mm), endometrial thickness (to normal
thickness of 6 mm) and not have considerable side effects in the patients. The primary
outcome measure was normal follicular size and the secondary outcome measure were the
clinical and current pregnancy rates. Clinical pregnancy was considered as the presence of a
gestational sac with fetal heart activity. Letrozole tablets were prescribed by an
experienced nurse who throughly explained the method of use to the patients. Sonography was
done by an experienced radiologist.
The nurse prescribed letrozole to the patients and the university hospital laboratory's
technician did not know past medical history of clomiphene resistance of the patients. The
radiologist did not have any knowledge about the drugs prescribed to the patients. Side
effects and complications of Letrozole were detailed to all patients by an obstetrician.
Statistical analysis was performed by the Statistical Package for Social Science version
11.5 for windows (SPSS Inc., Chicago. IL). The data was analyzed by student's t-test and
chi-squared test for linear trend and comparing proportions. A P-value of <0.05 was
considered to be statistically significant.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A |